Drug Sponsors

PharmAthene to cut two-thirds of staff

Wednesday, March 11, 2015 12:32 PM

Annapolis, Md.-based PharmAthene will launch a realignment plan that includes reducing its staffing levels by approximately two-thirds. Eric Richman, president and CEO, will remain a member of the board of directors but will no longer serve as an officer of the company, effective March 11. He will continue to play a key role in managing the ongoing litigation, other legal matters and strategic transactions in his role as director.

More... »


Concordia Healthcare to acquire Covis Pharma commercial assets for $1.2B

Wednesday, March 11, 2015 12:28 PM

Concordia Healthcare, a Canada-based diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population, will acquire substantially all of the commercial assets of privately held Covis Pharma and Covis Injectables, headquartered in Zug, Switzerland, for $1.2 billion in cash.

More... »


FDA approves first biosimilar Zarxio from Sandoz

Friday, March 6, 2015 12:24 PM

Sandoz, a Novartis company, has became the first company to receive approval of a biosimilar in the U.S. through the new FDA biosimilar pathway established under the Biologics Price Competition and Innovation Act.

More... »

Mallinckrodt Pharmaceuticals to acquire Ikaria

Friday, March 6, 2015 12:14 PM

Mallinckrodt, a global specialty biopharmaceutical company based in Dublin, through a subsidiary, will acquire Hampton, N.J.-based Ikaria, a privately held critical care company, from a Madison Dearborn-led investor group, in a transaction valued at approximately $2.3 billion.

More... »

AbbVie to acquire Pharmacyclics for $21B, boosting hematological oncology franchise

Thursday, March 5, 2015 12:38 PM

AbbVie has announced a definitive agreement to acquire Pharmacyclics and its flagship asset Imbruvica (ibrutinib), a treatment for hematologic malignancies. 

More... »

Baxter International acquires SuppreMol

Thursday, March 5, 2015 12:35 PM

Baxter International has acquired SuppreMol for approximately $225 million. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany, developing treatment options for autoimmune and allergic diseases.

More... »

Johnson & Johnson Innovation opens JLABS @South San Francisco

Wednesday, March 4, 2015 01:30 PM

Johnson & Johnson Innovation has opened JLABS @South San Francisco (JLABS @SSF), a 30,000-square-foot incubator located in South San Francisco, Calif. The Johnson & Johnson Innovation, JLABS site can accommodate up to 50 startups from across the healthcare spectrum including biotech, pharmaceutical, medical device, consumer and digital health. 

More... »

Malin to acquire Serenus Biotherapeutics

Wednesday, March 4, 2015 01:22 PM

Serenus Biotherapeutics, a San Francisco, Calif.-based specialty biopharmaceutical company, has secured investment of up to $43 million from Malin, an Ireland-based global life sciences company focused on healthcare.

More... »

Domain Therapeutics launches Kaldi Pharma

Wednesday, March 4, 2015 01:21 PM

Domain Therapeutics, a France-based biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), has created a Specific Purpose Vehicle (SPV), Kaldi Pharma, for the exclusive development of its A2a/A1 and A2a antagonist programs.

More... »

Cardinal Health to acquire Johnson & Johnson’s Cordis

Wednesday, March 4, 2015 01:18 PM

Johnson & Johnson has received a binding offer from Cardinal Health, a healthcare services company based in Dublin, Ohio, to acquire its Cordis business for an aggregate value of $1.99 billion, consisting of $1.944 billion of cash proceeds from Cardinal Health plus approximately $46 million of retained net receivables. Cordis is a developer and manufacturer of interventional vascular technology with 2014 net revenues of approximately $780 million.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs